<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527681</url>
  </required_header>
  <id_info>
    <org_study_id>BPR-PIP-001</org_study_id>
    <secondary_id>2013-004614-18</secondary_id>
    <nct_id>NCT02527681</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics</brief_title>
  <official_title>An Open-label Study to Evaluate the Single-dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment With Systemic Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to characterize the pharmacokinetics of single doses of
      ceftobiprole in neonates and infants aged ≤ 3 months. The secondary objective is to evaluate
      safety and tolerability of ceftobiprole in neonates and infants aged ≤ 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed maximum plasma concentration (Cmax) of ceftobiprole</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t½) of ceftobiprole</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity and to last observation (AUC o-inf; AUC o-t) of ceftobiprole</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic clearance (CLs) of ceftobiprole</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss) of ceftobiprole</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The length of time plasma concentrations of ceftobiprole exceed the minimum inhibitory concentration (T&gt;MIC)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically relevant findings in laboratory tests (including hematology, blood chemistry, urinalysis)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically relevant findings in vital signs</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Ceftobiprole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of ceftobiprole at 7.5 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftobiprole</intervention_name>
    <description>single dose of ceftobiprole at 7.5 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril</description>
    <arm_group_label>Ceftobiprole</arm_group_label>
    <other_name>ceftobiprole medocaril</other_name>
    <other_name>BAL5788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates and infants ≤ 3 months, with gestational age ≥ 28 weeks

          -  Documented or presumed (or at risk of) bacterial infections, and currently receiving
             antibiotic treatment

          -  Expected to survive beyond the first 7 days after enrolment

          -  Sufficient vascular access to receive study drug, and to allow blood sampling at a
             site separate from the study drug infusion site

          -  Parent's / legally acceptable representative's informed consent to participate in the
             study

        Exclusion Criteria:

          -  Major birth defect or malformation syndrome

          -  Proven presence of an immunodeficiency

          -  HIV or other congenital viral or fungal infection

          -  Significant laboratory abnormalities including: Haematocrit &lt; 20%; Absolute
             neutrophil count &lt; 0.5⋅10⁹/L; Platelet count &lt; 50⋅10⁹/L; Alanine aminotransferase or
             aspartate aminotransferase &gt; 3 times the age-specific upper limit of normal

          -  Impaired renal function or known significant renal disease

          -  Any condition which would make the subject or caregiver, in the opinion of the
             investigator, unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kaindl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnes Kaelin Aebi, PhD</last_name>
    <phone>+41 61 567 1534</phone>
    <email>agnes.kaelinaebi@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Kaindl, MD</last_name>
    <phone>+41 61 567 1505</phone>
    <email>thomas.kaindl@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vilnius University Children's Hospital</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 20, 2016</lastchanged_date>
  <firstreceived_date>August 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
